CRISPR Therapeutics CEO talks winning FDA approval for sickle cell anemia treatment

Samarth Kulkarni, CRISPR Therapeutics CEO, joins ’Closing Bell Overtime’ to talk winning FDA approval in the U.S. for sickle cell treatment in partnership with Vertex.